Julie Epple
General Practice · Festus, MONPI 1043242183
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 255 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by AbbVie at 39.7% of the total. Among general practice clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 255 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$519
- Lilly USA, LLC$396
- Novo Nordisk$353
- Pfizer$172
- Sumitomo Pharma America, Inc.$149
- plus $1K from 26 others
What the payments were for
- Food & beverage$4,704100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 95 | $1,870 |
| AstraZeneca | 29 | $519 |
| Lilly USA, LLC | 21 | $396 |
| Novo Nordisk | 21 | $353 |
| Pfizer | 11 | $172 |
| Sumitomo Pharma America, Inc. | 8 | $149 |
| GSK | 8 | $131 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $129 |
| Exact Sciences | 5 | $92 |
| Eisai Inc. | 2 | $85 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $79 |
| Amgen | 4 | $79 |
| Boehringer Ingelheim | 4 | $72 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $69 |
| Merck | 4 | $57 |
| Abbott | 3 | $52 |
| Johnson & Johnson | 2 | $42 |
| Edwards Lifesciences | 1 | $31 |
| Amarin Pharma, Inc. | 2 | $30 |
| Bayer | 2 | $27 |
| Dynavax Technologies Corporation | 1 | $20 |
| Medtronic | 1 | $19 |
| Valinor Pharma, LLC | 1 | $19 |
| Averitas Pharma Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Novartis | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
How this compares
$4,704 in reported general payments places this provider in the 95th percentile of 1,446 general practice providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 23 | $29,911 |
| OzempicSemaglutide | 14 | $27,632 |
| JardianceEmpagliflozin | 20 | $21,324 |
| XareltoRivaroxaban | 11 | $15,222 |
| TrulicityDulaglutide | 11 | $14,457 |
| Nurtec OdtRimegepant Sulfate | 13 | $13,062 |
| MyrbetriqMirabegron | 18 | $10,890 |
| LinzessLinaclotide | 13 | $10,130 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $8,152 |
| Repatha SureclickEvolocumab | 13 | $6,941 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 16 | $3,955 |
| Tolterodine Tartrate ErTolterodine Tartrate | 16 | $3,052 |
| Gabapentin | 150 | $2,964 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 32 | $2,510 |
| Omeprazole | 129 | $2,389 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $396 | $44,36834 claims |
| Novo NordiskOzempic | $353 | $27,63214 claims |
| Boehringer IngelheimJardiance | $72 | $21,32420 claims |
| PfizerNurtec Odt, Abrysvo | $172 | $17,01729 claims |
| Johnson & JohnsonXarelto | $42 | $15,22211 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $10,89018 claims |
| AbbVieLinzess | $1,870 | $10,13013 claims |
| AstraZenecaSymbicort | $519 | $8,15227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,446 general practice providers in Missouri.
Other general practice in Festus
- Baron GrutterGladstone$445K
- Arthur GreenbergKansas City$241K
- Robert CalaluceColumbia$189K
- Suraiya SiddiqueMount Vernon$61K
- John FluckeLees Summit$60K
- Rex HudsonSaint Louis$49K
- David KaelinCape Girardeau$27K
- Nadeemuddin QureshiSaint Louis$22K
- Michael McKenzieHannibal$20K
- Robert McGrawCameron$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.